For most 75-year-old women, starting systemic estrogen therapy is not a good idea. The evidence consistently shows that the benefits of hormone therapy are strongest when started near the time of menopause and diminish or reverse when started a decade or more afterward. At 75, a woman is typically more than two decades past menopause, and her cardiovascular, stroke, and cancer risk profiles all shift in ways that make systemic estrogen harder to justify. But the full picture has important exceptions: vaginal (local) estrogen is a genuinely different treatment with different risks, and a woman who has already been on hormone therapy for years faces a different set of decisions than one considering it for the first time.
Why the Timing of Estrogen Matters So Much
The single most important concept in this conversation is what researchers call the “timing hypothesis.” The idea is straightforward: estrogen appears to protect blood vessels when they are still relatively healthy, but once years of aging have stiffened and narrowed them, adding estrogen back does not reverse the damage and may make things worse.1PubMed Central. Vascular Aging in Women: is Estrogen the Fountain of Youth? A well-designed trial illustrated this clearly: among women who were fewer than six years past menopause, estrogen slowed the thickening of artery walls compared with placebo. Among women who were ten or more years past menopause, the same treatment had no benefit at all.2PubMed Central. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol
A similar pattern shows up in brain tissue. Animal research has found that long-term estrogen deprivation leads to a breakdown of estrogen receptors in the hippocampus, the brain region critical for memory. Once those receptors degrade, reintroducing estrogen no longer provides the neuroprotective effects it once did.3PubMed. Loss of Estrogen Efficacy Against Hippocampus Damage in Long-Term OVX Mice Is Related to the Reduction of Hippocampus Local Estrogen Production and Estrogen Receptor Degradation Extended periods without estrogen may also make the hippocampus more vulnerable to damage from reduced blood flow.4PubMed Central. Oestrogen signalling and neuroprotection in cerebral ischaemia In plain terms, a 75-year-old woman’s body has adapted to operating without significant estrogen for over two decades. The receptors and pathways that once responded to the hormone have changed, and the original protective window has closed.
Heart Disease and Stroke Risk After 60
Heart disease is the leading cause of death in older women, so any treatment that shifts cardiovascular risk even slightly matters a great deal. Meta-analyses have found that when hormone therapy is started in women younger than 60 or within ten years of menopause, it reduces the risk of coronary heart disease by roughly a third and cuts all-cause mortality by a similar margin. But when the same therapy is started in women over 60 or more than ten years past menopause, those benefits disappear entirely.5PubMed Central. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It’s About Time and Timing For a 75-year-old who has never taken hormone therapy, the expected cardiovascular benefit is essentially zero.
Stroke is an even more concerning picture. Evidence from clinical trials and observational studies consistently shows that standard-dose hormone therapy raises stroke risk by about a third, with the effect concentrated in ischemic stroke. For younger postmenopausal women, the absolute increase is small, roughly two additional strokes per 10,000 person-years. For older women, the absolute risk is considerably greater because their baseline stroke risk is already higher.6PubMed Central. Hormone therapy and the risk of stroke: perspectives ten years after the Women’s Health Initiative trials Clinical trials have also found that older women who still experience hot flashes have a markedly increased cardiovascular risk when they start oral hormone therapy, compared with older women who are asymptomatic.7Maturitas. Managing menopausal vasomotor symptoms in older women That finding is worth pausing on: the women who might most want hormone therapy at an advanced age because they still have bothersome symptoms are the same women who face the highest cardiovascular risk from starting it.
Cancer Considerations
Cancer risk adds another layer. Estrogen-plus-progestin therapy, the combination typically prescribed to women who still have a uterus, has consistently been linked to a higher risk of breast cancer. Data from the Women’s Health Initiative showed that combined hormone therapy raised breast cancer risk by about 24% during the treatment period, and that elevated risk persisted for years after stopping.8PubMed Central. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone Analyses of Data From Women’s Health Initiative Randomized Clinical Trials Estrogen alone, given to women who have had a hysterectomy, tells a different story: it showed little to no increase in breast cancer risk during treatment and may even have been slightly protective in the short term.9PubMed Central. Estrogens and breast cancer
On the other hand, estrogen without a progestin dramatically raises the risk of endometrial cancer. A meta-analysis found that women using unopposed estrogen had roughly 2.3 times the risk of endometrial cancer compared with nonusers, and that number climbed to about 9.5 times with ten or more years of use. The elevated risk persisted for at least five years after stopping.10PubMed. Hormone replacement therapy and endometrial cancer risk: a meta-analysis That is why any woman with an intact uterus who takes systemic estrogen must also take a progestin to counteract this risk.11PubMed Central. Menopausal hormone therapy and risk of endometrial cancer For a 75-year-old considering new hormone therapy, these cancer risks add to an already unfavorable risk-benefit calculation.
Bone Health at 75
Osteoporosis is one of the most commonly cited reasons for considering estrogen at older ages, and it is true that hormone therapy is highly effective at preserving bone density and reducing fracture risk, including hip fractures.12PubMed Central. Prevention and treatment of osteoporosis in women But there is an important catch: bone loss resumes at the post-menopause rate as soon as hormone therapy stops. That means estrogen does not build a lasting reserve of bone; it only protects bone for as long as you take it. A 75-year-old would need to continue indefinitely to maintain the benefit, and the accumulating risks of long-term use at that age generally outweigh the skeletal gains.
Several other medications are now available for osteoporosis in older women, including bisphosphonates, denosumab, and newer drugs that actively stimulate bone formation. These carry their own side effects but do not share estrogen’s cardiovascular or cancer risks, making them the standard choice for osteoporosis treatment in a woman well past menopause. Some clinicians note that older women who have never been on estrogen may not even need the doses once thought necessary for bone protection, and that lower doses can still provide meaningful skeletal benefit.13British Columbia Medical Journal. Hormone replacement therapy in older women: Benefits and risks
Vaginal Estrogen Is a Different Story
Much of the caution about estrogen in older women applies to systemic therapy, meaning pills, patches, or gels that raise estrogen levels throughout the body. Vaginal estrogen, applied locally as a cream, tablet, or ring, is a genuinely different treatment. It delivers small doses of estrogen directly to the vaginal and urethral tissues without raising blood levels nearly as much as systemic routes.14PubMed Central. Transdermal Hormonal Therapy in Menopause: Current Evidence and Personalized Approaches
Vaginal dryness, painful intercourse, and recurrent urinary tract infections are extremely common in women over 70, and low-dose vaginal estrogen is one of the most effective treatments available. Because systemic absorption is much lower than with oral or transdermal formulations, many guidelines consider vaginal estrogen safe for older women, including some with a history of breast cancer, though that remains a case-by-case decision. There is some systemic absorption, and one study found ultrasound changes in the uterine lining consistent with estrogen stimulation, though other studies did not, possibly due to differences in dosage form.15F&S Reviews. Vaginal estrogen and the prevention of recurrent urinary tract infection in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials The bottom line: a 75-year-old woman struggling with vaginal symptoms or recurrent UTIs has a much stronger case for vaginal estrogen than for systemic therapy, and most clinicians will prescribe it without the same degree of hesitation.
If She Is Already Taking Estrogen
The calculus changes substantially for a woman who started hormone therapy around menopause and is still on it at 75. She is not starting fresh on aged blood vessels; she has had continuous exposure, which may have preserved some of the vascular and tissue responsiveness that would otherwise have been lost. A large Danish register-based cohort study found that starting hormone therapy around the typical age of menopause, roughly 52, was associated with the lowest long-term mortality.16BMJ. Menopausal hormone therapy and long term mortality: nationwide, register based cohort study Long follow-up data from the Women’s Health Initiative found that while age-related differences in outcomes narrowed over time, the findings did not support using hormone therapy specifically to reduce chronic disease or death.17JAMA. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials
Stopping hormone therapy is not always simple, either. In a study of over 800 women who attempted to discontinue, three-quarters experienced hot flashes afterward, and those who failed to quit reported more trouble sleeping and more mood disturbances than those who succeeded.18PubMed Central. Factors Associated with Successful Discontinuation of Hormone Therapy While most guidelines advise using the lowest effective dose for the shortest necessary time, there is no hard cutoff age at which a long-term user must stop. The decision involves weighing her ongoing symptoms, her personal risk factors for breast cancer and cardiovascular disease, and whether she has tried tapering.
Transdermal Versus Oral Delivery
For women who do use systemic estrogen, the route of delivery matters. Transdermal estrogen, delivered through a patch or gel applied to the skin, bypasses the liver’s first-pass metabolism. This means it provides more stable hormone levels and appears to carry a lower risk of blood clots and stroke compared with oral estrogen pills.14PubMed Central. Transdermal Hormonal Therapy in Menopause: Current Evidence and Personalized Approaches For an older woman on continued therapy, many clinicians prefer a transdermal approach. This distinction is relevant at any age, but it becomes more consequential at 75, when baseline clotting risk is already elevated. It is worth noting that the large WHI trials primarily tested oral conjugated equine estrogens, so some of the risks identified in those trials may have been amplified by the oral route.
Non-Hormonal Alternatives for Persistent Hot Flashes
Although most hot flashes resolve within a few years of menopause, some women continue experiencing them well into their seventies and even eighties. For these women, newer non-hormonal medications offer a genuine alternative. Fezolinetant and elinzanetant, which target a specific brain pathway involved in temperature regulation, have been shown to reduce the frequency of hot flashes by at least half. In pooled trial data involving over 4,600 patients, elinzanetant at higher doses and fezolinetant at standard doses were both effective, with elinzanetant showing a somewhat larger reduction in frequency.19Maturitas. Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials These drugs avoid the cardiovascular, stroke, and cancer risks associated with estrogen, making them a more appropriate first-line treatment for a 75-year-old who still has bothersome hot flashes. Older non-hormonal options, including certain antidepressants and gabapentin, can also help, though they tend to be less effective and come with their own side-effect profiles.
What Estrogen Does Not Do at Any Age
One area where expectations sometimes outstrip the evidence is muscle preservation. Sarcopenia, the gradual loss of muscle mass and strength with aging, is a serious concern for older women and a major contributor to falls and frailty. It might seem plausible that estrogen would help, given its broad role in maintaining tissues throughout the body. But a study of nonobese women who had been on long-term estrogen replacement found that the prevalence of sarcopenia was just as high among them as among women not using estrogen, suggesting that estrogen does not protect against age-related muscle loss.20PubMed. Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy Resistance exercise and adequate protein intake remain the most effective tools for maintaining muscle in older adults, with or without hormone therapy.
If a Doctor Does Prescribe Systemic Estrogen to an Older Woman
There are rare situations where a clinician might consider low-dose systemic estrogen for an older woman, usually when symptoms are severe, non-hormonal alternatives have failed, and her individual risk profile is relatively favorable. In those cases, practical guidance suggests starting at half the usual dose, administered daily or on alternate days, and increasing slowly. Women who have gone many years without estrogen are more likely to experience side effects like bloating, breast tenderness, and vaginal discharge when they start. On the other hand, older women tend to have less breakthrough bleeding than younger women on the same therapy, though any bleeding at that age can be alarming and needs evaluation to rule out endometrial problems.13British Columbia Medical Journal. Hormone replacement therapy in older women: Benefits and risks
Major medical societies endorse hormone therapy for recently menopausal women with moderate-to-severe symptoms and without contraindications, but they do not extend that endorsement to routine initiation in older women.21Circulation. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Any older woman considering estrogen should expect her doctor to discuss her personal cardiovascular risk, her breast cancer risk, and whether she has tried alternatives first.
The WHI’s Long Shadow and How It Shapes This Conversation
Part of the reason this question is so fraught is the legacy of the Women’s Health Initiative. When WHI results were published in 2002, showing that combined hormone therapy increased the risk of heart disease, breast cancer, stroke, and blood clots, hormone therapy use plummeted from about 22% of women over 40 to less than 5% within a decade. Menopause education in medical schools and residency programs essentially vanished. Even formulations that were not tested in the WHI were abandoned.22JAMA. New Analysis of Women’s Health Initiative Data Aims to “Clear the Air” Over Menopausal Hormone Therapy The lasting effect is that many women now in their seventies went through menopause during the worst of the panic and either stopped therapy abruptly or never started it, sometimes forgoing treatment that would have been appropriate and beneficial at the time. The science has matured considerably since then, and the answer to “should she take estrogen” is more nuanced than a blanket yes or no, but the overcorrection from the WHI era still shapes how patients and doctors approach the question.
Disparities in Who Gets Offered Hormone Therapy
Research consistently shows that the question of whether to take estrogen is not equally available to all women. A study of ambulatory care visits found that Black women received hormone therapy prescriptions at roughly half the rate of White women, even after controlling for the type of physician, practice setting, and geographic region.23PubMed. Racial differences in hormone replacement therapy prescriptions More recent data from the VA system confirms that the pattern persists: Black women veterans were less likely to have menopause symptoms documented in their medical records and less likely to receive systemic hormone therapy. Hispanic women had similarly lower odds of receiving systemic treatment.24PubMed Central. Racial/Ethnic Disparities in the Diagnosis and Management of Menopause Symptoms among Midlife Women Veterans These gaps mean that by the time a woman reaches 75, whether she was ever offered hormone therapy at the appropriate time may have depended partly on her race and her access to a knowledgeable provider, not just her medical history. For women who were never given the option during the window when it could have helped most, the question of starting it decades later is shaped by an inequity that preceded it.